A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT01796171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 1/2 open-label three part study in patients with relapsed indolent Non-Hodgkin's lymohoma (NHL) (Parts A and C) or relapsed/refractory follicular lymphoma (FL) (Part B).
Study identification
- NCT ID
- NCT01796171
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 191 participants
Conditions and interventions
Conditions
Interventions
- 10 MBq/kg Betalutin Drug
- 15 MBq/kg Betalutin Drug
- 20 MBq/kg Betalutin Drug
- 40 mg lilotomab Drug
- 100 mg/m2 lilotomab Drug
- 60 mg/m2 lilotomab Drug
- Rituximab Drug
- 12.5 mBq/kg Betalutin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2012 (Actual)
- Primary completion
- Oct 25, 2022 (Actual)
- Completion
- Oct 27, 2022 (Actual)
- Last update posted
- Jun 21, 2024
2012 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Arkansas For Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| University of California, San Francisco (UCSF) | San Francisco | California | 94143 | — |
| Boca Raton Regional Hospital | Boca Raton | Florida | 33486 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Baylor College of Medicine | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01796171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01796171 live on ClinicalTrials.gov.